TORONTO, Sept. 27 /CNW/ - NeuroMedix Inc. ("NeuroMedix") (TSXV: NMX)
today announced that it has created a Medical and Scientific Advisory Board
("MSAB") panel of experts to help guide the clinical development of Minozac,
its lead compound for the treatment of Alzheimer's disease.
